These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 37981235

  • 1. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Monigle MC.
    Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235
    [Abstract] [Full Text] [Related]

  • 2. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 3. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [Abstract] [Full Text] [Related]

  • 5. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Khanani AM, Callanan D, Dreyer R, Chen S, Howard JG, Hopkins JJ, Lin CY, Lorenz-Candlin M, Makadia S, Patel S, Tam T, Gune S, of the Ladder Investigators.
    Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
    [Abstract] [Full Text] [Related]

  • 6. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.
    Sood S, Mandell J, Watane A, Friedman S, Parikh R.
    JAMA Ophthalmol; 2022 Jul 01; 140(7):716-723. PubMed ID: 35708679
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, all Archway Investigators.
    Ophthalmology; 2022 Mar 01; 129(3):295-307. PubMed ID: 34597713
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr 01; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR, Clements KM, Hulbert E, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein MC.
    Acta Ophthalmol; 2016 Aug 01; 94(5):441-8. PubMed ID: 27061020
    [Abstract] [Full Text] [Related]

  • 14. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun 01; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK, DRCR Retina Network.
    JAMA Ophthalmol; 2019 Dec 01; 137(12):1424-1432. PubMed ID: 31647496
    [Abstract] [Full Text] [Related]

  • 17. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G.
    Cochrane Database Syst Rev; 2020 May 05; 5(5):CD012208. PubMed ID: 32374423
    [Abstract] [Full Text] [Related]

  • 18. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
    IVAN Study InvestigatorsInstitute of Clinical Science, The Queen's University of Belfast, Belfast, Ireland. u.chakravarthy@qub.ac.uk, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.
    Ophthalmology; 2012 Jul 05; 119(7):1399-411. PubMed ID: 22578446
    [Abstract] [Full Text] [Related]

  • 19. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.
    Nielsen JS, Chang A, Holekamp NM, Cavichini-Cordeiro M, Lin SL, Heinrich D, Maass KF, Menezes A, Singh N, Pieramici DJ.
    Ophthalmol Retina; 2024 Dec 05; 8(12):1127-1139. PubMed ID: 38914294
    [Abstract] [Full Text] [Related]

  • 20. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
    Brown GC, Brown MM, Chaudhry I, Stein JD.
    JAMA Ophthalmol; 2021 Apr 01; 139(4):389-397. PubMed ID: 33538789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.